Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business

sevasemtenPositive

AI Analysis

Summary

Servier has completed its acquisition of Edgewise Therapeutics' muscular dystrophy business, gaining sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies, to strengthen its rare neurology portfolio.

Outcome Details

Acquisition completed

Importance:7/10

Sentiment:

0.60

acquisitionmuscular dystrophyrare diseaseneurologylate-stage

Related Companies

$MDCE

Read the original article

Published by PR Newswire Pharma on July 13, 2026 12:30 PM

Read Original